share_log

ElectroCore to Participate at Upcoming Investor Conferences

ElectroCore to Participate at Upcoming Investor Conferences

电子核心公司将参加即将举行的投资者大会
GlobeNewswire ·  2022/09/06 08:06

ROCKAWAY, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Goldberger, will be participating at the H.C. Wainwright 24th Global Investment Conference and Ladenburg Thalmann 2022 Healthcare Conference.

新泽西州罗克韦,9月2022年06日(环球网)--商业级生物电子医药公司电芯公司(纳斯达克代码:ECOR)今天宣布,电芯公司首席执行官丹·戈德伯格将参加H.C.温赖特第24届全球投资大会和拉登堡·塔尔曼2022年医疗大会。

H.C. Wainwright 24th Annual Global Investment Conference
Date:  Wednesday, September 14, 2022
Time: 12:30 - 1:00 PM EDT
Event: Fireside Chat

H.C.温赖特第24届全球投资年会
日期:2022年9月14日(星期三)
时间:美国东部夏令时下午12:30-1:00
活动:炉边聊天

Ladenburg Thalmann 2022 Healthcare Conference
Date: Thursday, September 29, 2022
Time: 3:30 - 3:55 PM EDT
Event: Presentation

拉登堡·塔尔曼2022年医疗会议
日期:2022年9月29日(星期四)
时间:美国东部夏令时下午3:30-3:55
事件:演示文稿

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

关于电子核心公司
Electrcore,Inc.是一家商业阶段的生物电子药物公司,致力于通过其非侵入性迷走神经刺激治疗平台改善患者的预后,最初专注于神经科多种疾病的治疗。该公司目前的适应症是丛集性头痛和偏头痛的预防性治疗,偏头痛和发作性丛集性头痛的急性治疗,青少年偏头痛的急性和预防性治疗,以及成人的阵发性偏头痛和持续性偏头痛。

For more information, visit .

有关更多信息,请访问。

Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital

投资者:
里奇·科克雷尔
CG资本
404-736-3838
邮箱:ecor@cg.Capital


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发